These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18485453)

  • 21. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N
    Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery.
    Lazo-Langner A; Rodger MA; Wells PS
    Clin Appl Thromb Hemost; 2009; 15(3):316-26. PubMed ID: 19028773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
    Turpie AG; Fisher WD; Bauer KA; Kwong LM; Irwin MW; Kälebo P; Misselwitz F; Gent M;
    J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement].
    Mouret P
    Hamostaseologie; 2002 Aug; 22(3):21-4. PubMed ID: 12215757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
    Schulman S; Lundström T; Wålander K; Billing Clason S; Eriksson H
    Thromb Haemost; 2005 Oct; 94(4):820-4. PubMed ID: 16270637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ximelagatran: an oral direct thrombin inhibitor.
    Dager WE; Vondracek TG; McIntosh BA; Nutescu EA
    Ann Pharmacother; 2004 Nov; 38(11):1881-97. PubMed ID: 15383641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
    J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
    Ford GA; Choy AM; Deedwania P; Karalis DG; Lindholm CJ; Pluta W; Frison L; Olsson SB;
    Stroke; 2007 Nov; 38(11):2965-71. PubMed ID: 17885258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ximelagatran.
    Choudhury A; Goyal D; Lip GY
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
    Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW
    J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee.
    Boudes PF
    Contemp Clin Trials; 2006 Oct; 27(5):432-40. PubMed ID: 16769255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S; Diamond GA; Weintraub WS
    J Am Coll Cardiol; 2005 Dec; 46(11):1986-95. PubMed ID: 16325029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
    Harenberg J; Jörg I; Weiss C
    Eur J Clin Pharmacol; 2006 Mar; 62(3):173-7. PubMed ID: 16416154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin.
    Fernlöf G; Sjöström BM; Lindell KM; Wall UE
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):667-74. PubMed ID: 19741508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
    Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
    Agnelli G; Haas S; Ginsberg JS; Krueger KA; Dmitrienko A; Brandt JT
    J Thromb Haemost; 2007 Apr; 5(4):746-53. PubMed ID: 17408408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
    Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
    Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.